Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient in order for improved patient outcomes.
View More ⏩
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
View More ⏩
Liver fibrosis is the major driver in liver disease progression. Prof. Romero-Gómez, Spain, reviews on NoninvasiveTests - NITs for screening, referral, and diagnosis of nonalcoholic fatty liver disease.
View More ⏩
Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.
View More ⏩
Dr. Marat Fudim (USA) reviews the interaction between NAFLD and Heart Failure with preserved Ejection Fraction (HFpEF), including highlights of the global prevalence rate of NAFLD.
View More ⏩
There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
View More ⏩
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
View More ⏩
Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He discusses what we know about microvesicles in NASH and the rationale to consider them as biomarkers in liver disease.
View More ⏩
Prof. Pierre Bedossa (France) exploring mandatory role liver biopsy plays in clinical trials for NASH and the need for a central pathologist.
View More ⏩
This liver meeting in 2019 is quite interesting…
View More ⏩
So the diabetologists are recognizing that they have…
View More ⏩